Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Secondary Review, 26933-26934 [2017-12123]
Download as PDF
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2017–12060 Filed 6–9–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Healthcare Infection Control Practices
Advisory Committee (HICPAC)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC), National
Center for Emerging and Zoonotic
Infectious Diseases (NCEZID) announces
a meeting of the aforementioned
committee:
Times and Dates:
9:00 a.m.–5:00 p.m., EDT, July 13, 2017
9:00 a.m.–12:00 p.m., EDT, July 14, 2017
Place: Centers for Disease Control and
Prevention, Global Communications
Center, Building 19, Auditorium B, 1600
Clifton Road NE., Atlanta, Georgia,
30329.
Status: Open to the public, limited
only by the space available. Time will
be available for public comment. The
public is welcome to submit written
comments in advance of the meeting.
Comments should be submitted in
writing by email to the contact person
listed below. The deadline for receipt is
June 30, 2017. All requests must contain
the name, address, and organizational
affiliation of the speaker, as well as the
topic being addressed. Written
comments should not exceed one singlespaced typed page in length and
delivered in 3 minutes or less. Members
of the public who wish to provide
public comments should plan to attend
the public comment session at the start
time listed. Please note that the public
comment period may end before the
time indicated on the agenda, following
the last call for comments. Written
comments received in advance of the
meeting will be included in the official
record of the meeting.
Purpose: The Committee is charged
with providing advice and guidance to
the Director, Division of Healthcare
Quality Promotion (DHQP), the Director,
National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
the Director, CDC, the Secretary, Health
and Human Services regarding (1) the
practice of healthcare infection
VerDate Sep<11>2014
17:28 Jun 09, 2017
Jkt 241001
prevention and control; (2) strategies for
surveillance, prevention, and control of
infections, antimicrobial resistance, and
related events in settings where
healthcare is provided; and (3) periodic
updating of CDC guidelines and other
policy statements regarding prevention
of healthcare-associated infections and
healthcare-related conditions.
Matters for Discussion: The agenda
will include updates on CDC’s activities
for prevention of healthcare associated
infections (HAIs), an update on the
Division of Healthcare Quality
Promotion’s (DHQP) modeling
activities, updates on the Guideline for
Prevention of Infection in Neonatal
Intensive Care Unit (NICU) Patients and
the Guideline for Prevention of Infection
in Healthcare Personnel, and updates
from the following HICPAC workgroups:
The workgroup on antibiotic
stewardship principles for inclusion
into clinical practice guidelines, the
workgroup on updating the CDC
recommendation categorization scheme,
the workgroup on developing CDC
recommendations for products and
practices, and the National Healthcare
Safety Network (NHSN) Surveillance
Workgroup.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Erin Stone, M.A., HICPAC, Division of
Healthcare Quality Promotion, NCEZID,
CDC, l600 Clifton Road NE., Mailstop
A–07, Atlanta, Georgia 30329,
Telephone (404) 639–4045. Email:
hicpac@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–12122 Filed 6–9–17; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
26933
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Secondary
Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the secondary
review of applications in response to
Funding Opportunity Announcements
(FOAs), CE17–003, Research Grants for
Preventing Violence and Violence
Related Injury (R01); and PHS 2016–02
Omnibus Solicitation of the NIH, CDC
FDA, and ACF for Small Business
Innovation Research Grant Applications
(Parent SBIR [R43/R44]).
Time and Date: 8:00 a.m.–5:00 p.m.,
EDT, July 18, 2017 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the secondary review,
discussion, and evaluation of
applications received in response to
FOAs ‘‘Research Grants for Preventing
Violence and Violence Related Injury
(R01)’’, CE17–003; and ‘‘PHS 2016–02
Omnibus Solicitation of the NIH, CDC
FDA, and ACF for Small Business
Innovation Research Grant Applications
(Parent SBIR [R43/R44])’’.
Contact Person for More Information:
Gwendolyn H. Cattledge, Ph.D.,
M.S.E.H., Deputy Associate Director for
Science, National Center for Injury
Prevention and Control, CDC, 4770
Buford Highway NE., Mailstop F–63,
Atlanta, Georgia 30341, Telephone (770)
488–1430.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
E:\FR\FM\12JNN1.SGM
12JNN1
26934
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–12123 Filed 6–9–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0493]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Utilization of
Adequate Provision Among Low to
Non-Internet Users
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on research entitled
‘‘Utilization of Adequate Provision
among Low to Non-Internet Users.’’
DATES: Submit either electronic or
written comments on the collection of
information by August 11, 2017.
ADDRESSES: You may submit comments
as follows:
SUMMARY:
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
VerDate Sep<11>2014
17:28 Jun 09, 2017
Jkt 241001
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2017–N–0493 for ‘‘Utilization of
Adequate Provision among Low to NonInternet Users.’’ Received comments
will be placed in the docket and, except
for those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: For
copies of the questionnaire: Office of
Prescription Drug Promotion Research
Team, DTCresearch@fda.hhs.gov. For
questions on the PRA: JonnaLynn
Capezzuto, Office of Operations, Food
and Drug Administration, Three White
Flint North, 10A63, 11601 Landsdown
St., North Bethesda, MD 20852, 301–
796–3794.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
E:\FR\FM\12JNN1.SGM
12JNN1
Agencies
[Federal Register Volume 82, Number 111 (Monday, June 12, 2017)]
[Notices]
[Pages 26933-26934]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-12123]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Secondary Review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces a meeting for the secondary review of
applications in response to Funding Opportunity Announcements (FOAs),
CE17-003, Research Grants for Preventing Violence and Violence Related
Injury (R01); and PHS 2016-02 Omnibus Solicitation of the NIH, CDC FDA,
and ACF for Small Business Innovation Research Grant Applications
(Parent SBIR [R43/R44]).
Time and Date: 8:00 a.m.-5:00 p.m., EDT, July 18, 2017 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters for Discussion: The meeting will include the secondary
review, discussion, and evaluation of applications received in response
to FOAs ``Research Grants for Preventing Violence and Violence Related
Injury (R01)'', CE17-003; and ``PHS 2016-02 Omnibus Solicitation of the
NIH, CDC FDA, and ACF for Small Business Innovation Research Grant
Applications (Parent SBIR [R43/R44])''.
Contact Person for More Information: Gwendolyn H. Cattledge, Ph.D.,
M.S.E.H., Deputy Associate Director for Science, National Center for
Injury Prevention and Control, CDC, 4770 Buford Highway NE., Mailstop
F-63, Atlanta, Georgia 30341, Telephone (770) 488-1430.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and
[[Page 26934]]
Prevention and the Agency for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2017-12123 Filed 6-9-17; 8:45 am]
BILLING CODE 4163-18-P